Skip to Content

Intuitive Surgical Inc - Stock Quote ISRG

Rating as of

Morningstar's Intuitive Surgical Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Strong Procedure Growth but Capital Placements Decelerate for Intuitive

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

For us, procedure growth is the primary factor when assessing Intuitive's competitive positioning and long-term growth prospects. Thus, we call the firm's first quarter a relative success. Procedures, even despite minor omicron-related delays, were up 19% in the quarter globally and 16% in the U.S., which allowed Intuitive to slightly raise its procedure guidance. Most of the questions on the conference call, however, were about capital placements, which we have long assumed will continue to decelerate, which they did in the quarter. We maintain our full-year forecast and our fair value estimate for the firm. Our wide moat rating is unchanged.

Read Full Analysis

Intuitive Surgical Inc's Company Profile

Business Description

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 6,000 da Vinci systems in hospitals worldwide, with nearly 4,000 installations in the United States and a growing number in emerging markets.

Contact
1020 Kifer Road
Sunnyvale, CA, 94086-5304
T +1 408 523-2100
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 9,793

Intuitive Surgical Inc's Related News